Apitope presents at 2nd Antigen-Specific Immune Tolerance Summit Boston MA 2019

HASSELT, Belgium, and CHEPSTOW, UK, 29 March 2019 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, announces that Chief Research Officer Dr Lotta Jansson and Chief Scientific Officer Professor David Wraith attended and presented  at the  2nd Antigen-Specific Immune Tolerance Summit Boston MA 2019  conference held on 26 -28 March 2019.

27 March 2019

Presentation: Antigen-Specific Immunotherapy for Treatment of Autoimmune

Presenter: Professor David Wraith

The presentation was part of the session ‘Addressing Knowledge Gap in Immune Tolerance Induction by Connecting the Dots Between Transplantation, Allergies & Autoimmune Diseases’

27 March 2019

Panel Discussion: How to Identify & Prioritize the Route to Success for Antigen-Specific Immune Tolerance Induction Strategies?

Dr Lotta Jansson joined a panel discussion along with Charlotte Fribert, Toleranzi AB (Moderator), Matthias von Herrath, Novo Nordisk, David Alleva, Akston Biosciences and Joshua Sestak, Orion BioScience

The panel was part of the session on ‘Advancing Pre-Clinical Development of Novel Antigen-Specific Immune Tolerance Therapies’

28 March 2019

Panel Discussion: Evaluation of Combination Therapies to Address Unmet Clinical Needs

Dr Lotta Jansson joined a panel discussion along with David Alleva, Akston Biosciences, Amy Rosenberg, CDER/FDA and Pieter Rottiers, ActoBio Therapeutics. The panel was part of the session ‘The Future Landscape of Antigen-Specific Immune Tolerance Therapies: The Promise of Combination Strategies’ 

A poster was also presented at the meeting  entitled ‘Treating autoimmune diseases with tolerogenic peptides – apitopes®